Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lessons Learned In Immuno-Oncology From Former Roche Exec Dan Chen

Executive Summary

In an audio interview from the recent ASCO-SITC meeting, Chen weighs in on comparisons of PD-1 and PD-L1 inhibitors, the IDO failures, biomarkers and his new work at the private biotech IGM Biosciences.

Advertisement

Related Content

Appointments: Senior Hires At IGM, Cell Medica, Mologen, Navitor, Tenaya, Oncobiologics, Provention Bio And Centrexion
Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO
Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space
Roche Pushes The Boundaries Of Cancer Immunotherapy
INTERVIEW: Roche's Dan Chen Talks Immuno-Oncology Combinations
Beyond PD-1: Roche Maps Further Checkpoints On Cancer Immune Cycle

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel